Literature DB >> 27441742

Growing Evidence Supports the Use of Radiation Therapy in Unresectable Intrahepatic Cholangiocarcinoma.

Kyle C Cuneo1, Theodore S Lawrence.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27441742     DOI： 10.1097/PPO.0000000000000212

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


× No keyword cloud information.
  5 in total

1.  Wip1 is associated with tumorigenity and metastasis through MMP-2 in human intrahepatic cholangiocarcinoma.

Authors:  Sulai Liu; Bo Jiang; Hao Li; Zili He; Pin Lv; Chuang Peng; Yonggang Wang; Wei Cheng; Zhengquan Xu; Wei Chen; Zhengkai Liu; Bao Zhang; Shengqian Shen; Shuanglin Xiang
Journal:  Oncotarget       Date:  2017-05-23

2.  iNOS is associated with tumorigenicity as an independent prognosticator in human intrahepatic cholangiocarcinoma.

Authors:  Sulai Liu; Jinqiong Jiang; Linsheng Huang; Yu Jiang; Nanhui Yu; Xiehong Liu; Yuan Lv; Hao Li; Lianhong Zou; Chuang Peng; Xing Yu; Bo Jiang
Journal:  Cancer Manag Res       Date:  2019-08-26       Impact factor: 3.989

3.  Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis.

Authors:  Jieqiong Liu; Meizuo Zhong; Yuhua Feng; Shan Zeng; Yikai Wang; Hongbo Xu; Hui Zhou
Journal:  Transl Oncol       Date:  2019-08-22       Impact factor: 4.243

4.  Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis.

Authors:  Jianping Zhao; Yao Chen; Jingjing Wang; Jian Wang; Ying Wang; Songshan Chai; Yuxin Zhang; Xiaoping Chen; Wanguang Zhang
Journal:  BMC Surg       Date:  2021-03-06       Impact factor: 2.102

5.  Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study.

Authors:  Tian-Hua Yu; Xin Chen; Xuan-He Zhang; Er-Chi Zhang; Cai-Xia Sun
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.